Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Best outcome

will be for PTSC to put out a PR saying that they will terminate the legal proceedings and all future activities; will distribute the money stashed away from previous license fees among shareholders as a final dividend and apply to delist and dis-enroll as a company! We might still make away with a $0.05-$0.07 per share

Share
New Message
Please login to post a reply